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Abstract
Oncolytic adenoviruses can be engineered for better tumor selectivity, gene delivery and be armed for imaging and
concentrating radionuclides into tumors for synergistic oncolysis. We constructed Ad5/3-hTERT-hNIS where replication is
controlled by hTERT-promoter. Ad5/3-hTERT-hNIS expresses hNIS for imaging of transgene expression and for treatment
of infected tumors by radioiodine. Ad5/3-hTERT-hNIS efficiently killed prostate cancer cells and induced iodine uptake in
vitro and in vivo after intratumoral virus administration. Survival of mice treated with intravenous Ad5/3-hTERT-hNIS
significantly prolonged survival over mock or radioiodine only but the combination of virus with radioiodine was not
more effective than virus alone. Temporal and spatial changes in hNIS-expression during therapy were detected with
SPECT, demonstrating feasibility of evaluation of the combination therapy with hNIS-expressing adenoviruses and
radioiodide.
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Introduction
Gene therapy with oncolytic viruses is an emerging experimen-
tal option for treating refractory cancer lacking curative therapies.
This is the case for castration resistant prostate cancer that killed
estimated 27,000 men in 2009 in the U.S (http://www.cancer.
gov/cancertopics/types/prostate). Oncolytic adenoviruses are
promising therapeutic tools since the infection results in cytolysis
of transduced cells and in the release of therapeutic progeny for
further spread into target tumors. The feasibility of genetic
alteration of the adenoviral genome has led to the development of
several modifications that render these agents cancer selective
[1,2]. Consequently, oncolytic adenoviruses have been successfully
used in clinical trials, including prostate cancer patients [3].
However, although proven safe, the efficacy of the treatments still
needs to be improved. One means to achieve this is to combine
them with chemotherapeutics and radiation [4,5,6].
Human sodium/iodide symporter (hNIS) is a transmembrane
protein that is located on the basolateral membrane of thyroid cells
and actively transports iodine (I2) for thyroid hormone synthesis.
The ability to accumulate I2 via hNIS has provided the basis for
diagnostic scintigraphic imaging in thyroid cancer and has been an
effective means to target radioiodine for its treatment. The
structure of oncolytic adenoviruses is compatible with the insertion
of therapeutic molecules as transgenes and this feature has also
been exploited for delivery of hNIS [7,8,9]. Recently, we and
others have successfully used adenovirus-encoded hNIS to
transport 131I into cancer cells for a combined antitumoral effect
[7,10]. In addition, hNIS-expression not only provides a
therapeutic means to improve efficacy but also might serve as an
imaging tool for assessing tumor size and provides information on
viral kinetics during the treatment.
Recent developments in dedicated small animal multi-detector
and multi-pinhole collimator scanners for single photon emission
computed tomography (SPECT) have rendered the modality a
powerful tool in preclinical imaging. Decades of clinical use have
resulted in many commercially available tracers and kit-formula-
tions for facile tracer radiolabeling easing the adaptation of the
technique also to preclinical use. SPECT has been successfully
employed in the visualization of various transgenes [11], but its
advantages over other imaging modalities have rarely been more
pronounced than for hNIS-imaging, where selective, readily
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available and inexpensive probes, 131I2, 123I2 and 99mTcO4
2, can
be employed [10].
Telomeres are structures at the ends of chromosomes consisting
of hundreds to thousands of TTAGGG-repeats and associated
proteins [12]. During each mitotic cell division several telomeric
repeats are lost. However, some cell types, including stem and
cancer cells, maintain the capacity of indefinite renewal by
expressing telomerase [13], a ribonucleotide protein that can
synthesize telomeres de novo. In fact, genetic mutations leading to
constitutively active telomerase-expression have been associated
with most human cancers [14]. Human telomerase reverse trans-
criptase (hTERT) is the catalytic subunit of human telomerase and
is the major determinant of telomerase activity [15]. Since hTERT
is mostly active in tumor cells, or in stem cells (not effectively killed
by oncolytic adenoviruses) [16], hTERT-activity can be exploited
for cancer gene therapy. This approach has been successfully used
in the context of genetically modified adenoviruses to obtain
tumor-specific replication not only in preclinical models [17,18]
but also in one clinical trial [19].
Gene expression by oncolytic adenoviruses is determined in part
by their capability to enter target cells [20]. However, the native
receptor for Ad5, coxsackie and adenovirus receptor (CAR), is
often poorly expressed on cancer cells [1]. Alternative targeting
strategies have been developed to overcome this and several
genetic modifications of the adenoviral capsid and knob have
resulted in better tumor transduction [21]. One approach includes
the replacement of Ad5 knob with the serotype 3 knob since, as
compared to CAR, the Ad3 receptor is expressed to a higher
degree on cancer tissue and is different from CAR [22,23,24].
In the present study, we constructed Ad5/3-hTERT-hNIS
where viral replication is controlled by the hTERT-promoter.
Ad5/3-hTERT-hNIS is targeted to the Ad3 receptor for effective
tumor transduction and expresses hNIS in replication-permissive
cells only, thus allowing imaging of viral replication and treatment
of infected tumors by radioactive iodine.
Results
Ad5/3-hTERT-hNIS expresses functional hNIS and is able
to mediate iodine uptake into prostate cancer cells
Two new oncolytic adenoviruses, Ad5/3-hTERT-hNIS and its
control virus Ad5/3-hTERT- Dgp19K, were constructed to study
their antitumor effect against castration resistant prostate cancer.
The Ad5 knob was replaced by the Ad3 knob to increase
transduction of cancer cells [22]. The native E1A promoter was
replaced by an hTERT-promoter for tumor-specific replication. In
Ad5/3-hTERT-hNIS, the gp19K and 6.7K in E3 is replaced by
hNIS that remains under the native E3-promoter and results in
replication-coupled transgene expression that starts circa 8 h post-
infection [25]. The control virus harbors the same deletion (gp19K
and 6.7K) without insertions.
To test the capability of the viruses to induce the expression of
hNIS, castration resistant prostate cancer cells were infected with
the new viruses and the cells were collected for hNIS RT-PCR at
24 h or 48 h afterwards (Figure 1a). Ad5/3-hTERT-hNIS dis-
played strong induction of hNIS at both time points whereas
the control virus -infected cells remained negative for hNIS-
expression.
Since mRNA-expression does not automatically mean produc-
tion of functional hNIS, the ability of infected cells to transport
and concentrate iodine was evaluated. Ad5/3-hTERT-hNIS-
infected prostate cancer cells were incubated with 125I and then
analyzed for iodide uptake using a gamma-counter (Figure 1b).
24 h after infection, iodide uptake was significantly higher in Ad5/
3-hTERT-hNIS infected than in mock treated cells, p,0.001 for
22Rv1 and PC-3MM2 and p= 0.003 and 0.002 for PC-3 and DU-
145 cells, respectively. Significant differences were sustained at
48 h (p,0.001 for PC-3 and 22Rv1 and 0.04 and 0.003 for DU-
145 and PC-3MM2 cells, respectively). PC-3 cells seemed to
accumulate some radioiodine also without virus treatment. The
phenomenon has also been reported previously for other cancer
types and it is known that many secretory tissues, such as the
prostate, feature a weak capacity to actively transport iodide
[26,27]. This suggests that possibly hNIS-independent uptake of
iodine impacted the results of the in vitro study.
Ad5/3-hTERT-hNIS mediates effective oncolysis of
prostate cancer cells in vitro
To determine the oncolytic capacity of the new viruses, prostate
cancer cell lines were infected with viruses and cell viability was
assessed by the 3-(4,5,dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)- 2-(4-sulfophenyl)-2H –tetrazolium inner salt (MTS) assay
(Figure 2). Here, cell survival after infection is followed daily and
the assay is stopped when the fastest virus has caused almost
complete cell killing at the highest dose. In most cell lines, Ad5/3-
hTERT-hNIS was more potent than wild-type adenovirus.
However, some variation in the killing of different cell lines was
observed, as also previously reported [24].
In the majority of the cell lines, the transgene-less Ad5/3-
hTERT-Dgp19K was more efficient in prostate cancer cell killing
than Ad5/3-hTERT-hNIS (Figure 2). This may be explained by
the larger genome size of Ad5/3-hTERT-hNIS, caused by the
transgene, which has been reported to affect oncolytic potency
[7,10].
Iodine uptake into tumors in vivo
To evaluate the ability of Ad5/3-hTERT-hNIS to direct iodine
uptake into prostate tumors in vivo, a subcutaneous tumor model
was established. Each mouse had four PC-3MM2 tumors
(Figure 3a). Two lowermost tumors were injected twice with
Ad5/3-hTERT-hNIS and others with Ad5/3-hTERT-Dgp19K
(upper right tumor) or mock (upper left tumor). To follow the
kinetics of iodine accumulation into these tumors 24 h later, mice
received intravenous 123I followed by a series of gamma-camera
imaging between 0.5 h and 13 h after iodine administration. As
seen in Figure 3a, Ad5/3-hTERT-hNIS allows in vivo accumula-
tion of systemic radioiodine into tumors. Iodine concentration
reached a plateau at 2 h post iodine-injection and remained steady
until the last imaging at 13 h (Figure 3a). The variation in signal
between the Ad5/3-hTERT-hNIS injected tumors is likely due to
difference in tumor size as smaller tumors might have fewer blood
vessels (hampering iodine access to the tumor) and may not
contain as many tumor cells that allow for hNIS-expression.
123I accumulation was detected in the thyroid and stomach due
to endogenous expression of NIS in these organs. Bladder
visualization occurs due to excretion of 123I into urine [28]. Due
to animal regulations, the experiment was ended at 13 h and did
not permit us to study the effect of the treatment on tumor size.
Efficacy of Ad5/3-hTERT-hNIS in vivo
To study the antitumor efficacy of intravenously administered
Ad5/3-hTERT-hNIS with 131I in vivo, a survival experiment was
set up. PC-3MM2 cells were injected into the left lung of nude/
NMRI male mice (n = 12 mice/group) to mimic aggressive,
castration resistant, lung-metastatic prostate cancer. A week after
cell injection, the mice received 561010 vp of Ad5/3-hTERT-
hNIS or diluent intravenously. The next day, mice were
Systemic Delivery and Imaging of Ad5/3-hTERT- hNIS
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administered 37 MBq of therapeutic radionuclide 131I or PBS
intraperitoneally. This treatment-cycle was repeated once a week
for a total of three weeks.
The median survival in the mock group was 19.5 days
(Figure 3b). Survival prolongation was seen in the Ad5/3-
hTERT-hNIS+131I group where the median survival was 28
days. This was confirmed by statistical analyses where the p-value
between mock and Ad5/3-hTERT-hNIS+131I was ,0.001 and
between 131I only and Ad5/3-hTERT-hNIS+131I it was 0.007. As
expected, 131I only (20.5 days) did not increase survival. Although
intravenous delivery of oncolytic adenovirus presents many
challenges, and the model used is particularly aggressive, the
overall survival of virus-only treated mice was improved over mock
treatment (p = 0.04). Also, one mouse was tumor-free and healthy
at the end of the experiment. Survival in the virus +131I group was
not improved over virus –only treatment.
As radioidide might also accumulate into organs passively, or as a
result of non-tumor-specific hNIS-expression, we measured the
radioactivity of different organs - including tumors - from three mice
from the Ad5/3-hTERT-hNIS+131I group, killed 24 hours after the
first iodide injection (48 h after first virus injection). Due to the
endogenous expression of NIS in the thyroid and stomach, about
320% and 15% of the injected dose per gram of tissue (ID/g) was
concentrated in these organs, respectively. Iodide uptake into tumor
was 1.3% of the injected dose (Figure 3c). The high ID/g of thyroid
reflects the uneven distribution of iodine: if iodine would accumulate
evenly into each organ, the ID/g would be 100%/organ.
In vivo imaging of hNIS-expression by SPECT/CT after
systemic administration of Ad5/3-hTERT-hNIS
While there was a survival improvement in both virus groups
over no treatment or iodine only, radioiodide did not improve
survival significantly. Therefore, we performed imaging-experi-
ments to investigate reasons for this. This permitted us also to
assess the feasibility of hNIS-mediated imaging. A similar setting to
the survival-experiment was employed, where mice received either
vehicle, Ad5/3-hTERT-hNIS only or Ad5/3-hTERT-hNIS+131I.
In addition, each group received 24 h after each virus/vehicle
administration an intravenous bolus of 123I2 for imaging, followed
by a SPECT/CT-scan and quantitation of the 123I2 signal. After
the first injection, 123I2 uptake in the lungs was low and no clear
tumor uptake was observed in mice treated with Ad5/3-hTERT-
hNIS 6 131I. At this early point, 123I2 uptake to the tumors was
not distinguishable from the background activity, which remained
at 0.0013860.0006%ID/mm3 throughout the study (Figure 4a).
This result is in accordance with the observed low tumoral iodine
uptake in the biodistribution assay (Figure 3c). After the second
viral injection, 3/5 of the virus-treated animals showed increased
123I2 uptake in tumors, however the level of 123I2 accumulation
was modest. The clearest 123I2 accumulation was reached after
the third virus-injection, reaching at highest 0.0035%ID/mm3
(Figures 4a and 5a, c). There was no difference in tumoral 123I2
accumulation between the two Ad5/3-hTERT-hNIS treated
groups, regardless if they received also the therapeutic isotope
131I in addition to the imaging isotope (Figure 4a). In comparison
Figure 1. hNIS-expression in prostate cancer cells. (a) Cells were infected with 10 vp of Ad5/3-hTERT-hNIS (lanes 1 and 3) or control virus Ad5/
3-hTERT-Dgp19K (lanes 2 and 4). hNIS-RNA -expression was assayed 24 h (lanes 1 and 2) and 48 h (lanes 3 and 4) later by RT-PCR. ß-actin served as an
internal control. (b) 125I uptake in prostate cancer cells infected in triplicates with 10 vp of Ad5/3-hTERT-hNIS or Ad5/3-hTERT-Dgp19K. The capability
of the cells to concentrate iodide was assessed at 24 h and 48 h after infection. Student’s t-test was used for statistical analyses, *p,0.05, **p,0.01,
***p,0.001 as compared to uninfected cells. Bars represent SD.
doi:10.1371/journal.pone.0032871.g001
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to mice that were not treated with the virus, the difference in
tumor signal was clear (Figure 5). The 123I2 uptake-results are
summarized in Table 1.
These data suggest that intravenous injections of Ad5/3-
hTERT-hNIS allow tumor transduction, virus replication, hNIS-
expression and radioiodide accumulation to such degree that it can
be detected with SPECT/CT. The signal volume detected by
SPECT was rather small and the mice nevertheless died, which led
us to perform autopsies at the end of the therapeutic experiment.
There was a discrepancy between actual tumor size seen in
autopsy and the radioiodide accumulation dependent SPECT
signal: tumors seemed larger than what was observed by SPECT
signal. Possible explanations for this include incomplete penetra-
tion of the tumor by either virus or by 123I2.
All animals showed normal endogenous NIS expression in the
thyroid, stomach, salivary and lachrymal glands. With the
exception of the thyroid in 131I-treated animals, iodide accumu-
lation into tissues expressing endogenous NIS was not affected. As
the thyroid was not protected from radioiodide uptake in this
experimental design, animals treated with 131I showed diminished
thyroid activity in the second and third SPECT scan, as expected
(Figure 4b). In addition, some mice showed physiological 123I2
uptake in the esophagus, which was easily differentiated from the
tumoral uptake using the anatomical information of the co-
registered CT scan (Video S1).
Dose ratios (approximated as uptake ratios) thyroid:blood:kid-
ney:tumor were approximately 1000:1.4:1.0:0.8 (Figure 3c). If the
thyroid is protected or thyroid ablation accepted, the dose limiting
normal tissue would be the red bone marrow. Assuming that the
blood dose can be used as a surrogate for the bone marrow dose
(i.e., assuming no active iodine trapping from blood to bone
marrow and cross-dose omitted), the typical highest allowed blood
dose (2 Gy/treatment cycle) would contribute 1.1 Gy to the tumor
which is perhaps unlikely to result in therapeutic effect. These
figures can be compared with the standard human kinetics applied
for the dosimetry of internal radiopharmaceuticals (sodium iodide,
oral administration, [29]) assuming 25% uptake of iodine in the
thyroid at 24 h. These calculations result in thyroid:bone
marrow:kidney ratios of 1000:2.4:1.05, respectively, which are in
the same range as the mouse figures reported here.
After intravenous adenovirus injections, a large proportion of
the dose is taken up by the liver [30]. Therefore, we analyzed the
hepatic radioiodide signal which would reflect ‘‘leaky’’ expression
of virally-encoded hNIS in a non-target organ, keeping in mind
that our virus-design predicts hNIS-expression mostly in cells that
allow virus replication. Only two out of five virus-treated animals
showed any degree of liver accumulation of 123I2 after the first
virus-treatment. This is in dramatic contrast to non-regulated
expression of transgenes following intravenous adenovirus injec-
tion [31]. After subsequent virus injections during the next two
weeks, no iodide uptake was detected (Figure S1) and the signal
difference compared to non-virus treated mice was insignificant
(p = 0.24). This demonstrated that hNIS-expression from Ad5/3-
hTERT-hNIS was mostly restricted to tumor cells and leaky
expression in normal tissues was minimal (Video S1).
Discussion
Several tissue-specific promoters have been exploited for
targeting oncolytic adenoviruses and restricting their gene
expression to target tumors [32]. While stringent tissue-specificity
has been reported, the drawback of this approach lies in the
selectivity of replication in only one or a few tumor types.
However, hTERT-expression is ubiquitous in most human tumors
Figure 2. Oncolytic potency of Ad5/3-hTERT-hNIS. Prostate cancer cells were infected in triplicates with 0.01 to 100 vp/cell and the cell viability
was assessed by MTS-assay. Ad5/3Luc1 is a replication-deficient adenovirus. Ad5 WT is the serotype 5 wild-type adenovirus. Ad5/3-hTERT-Dgp19K is
similar to Ad5/3-hTERT-hNIS but does not contain hNIS. ***p,0.001 as compared to replication-deficient adenovirus. Bars represent SD.
doi:10.1371/journal.pone.0032871.g002
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while limited in normal somatic cells [14], making it an attractive
promoter for specific adenoviral replication in human tumors.
Importantly, good safety data has been obtained in a human trial
featuring an hTERT-controlled oncolytic adenovirus [19].
hTERT is expressed in stem cells. However, since stem cell
toxicity is not an established feature of wild type adenovirus
infection [33], we can assume that stem cells have other ways to
protect themselves against virus as suggested by preliminary
experiments performed in normal breast stem cells [16]. Although
this study used Ad5/3-hTERT-hNIS to treat castration resistant
prostate cancer, Ad5/3-hTERT-hNIS could also be used to kill
hTERT-positive cancer cells of different origins.
The rationale for using hNIS in cancer gene therapy has already
been established [7,8,9,34]. In our virus, replication-induced
hNIS–expression from the adenoviral E3-region couples radio-
graphic imaging via hNIS to viral replication kinetics. We found it
feasible to assess these aspects by using SPECT. Moreover, hNIS-
expression by Ad5/3-hTERT-hNIS could allow dual-modality
destruction of infected tumors: therapeutic radioiodide-treatment
and oncolysis. While the same cell does not need to be killed twice,
the biggest utility might come from the two different bystander
effects. Oncolysis can amplify the input virus dose and in theory
the process continues as long as permissive cells exist. However,
tumors are complex, heterogeneous and contain areas impassable
Figure 3. In vivo iodide uptake and efficacy. (a) Tumor uptake of
123I2 0.5 h, 2 h and 13 h after i.v. administration of 123I2. The tumors
were injected twice with hTERT-viruses 24 h and 48 h prior to
radioiodide. 1, Mock-injected tumor; 2, Ad5/3-hTERT-Dgp19K-injected
tumor; 3 and 4, Ad5/3-hTERT-hNIS-injected tumors. (b) Ad5/3-hTERT-
hNIS significantly prolongs the survival of mice bearing intra pulmonary
PC-3MM2 tumors. Mice received 561010 vp of Ad5/3-hTERT-hNIS or
diluent intravenously. Next day, the mice were injected intraperitoneally
with 131I2. The treatments were repeated once a week for a total of
three weeks. Pairwise comparisons with the logrank test were used to
compare survival curves, **p,0.01, ***p,0.001 as compared to mock-
treated mice. (c) Biodistribution of 131I2 in mice 48 h after the first
intravenous Ad5/3-hTERT-hNIS-injection and 24 h after first radioiodide-
injection. Bars represent SD.
doi:10.1371/journal.pone.0032871.g003
Figure 4. SPECT/CT is sensitive for detecting endogenous NIS-
and hNIS-expression. Mice were given Ad5/3-hTERT-hNIS or diluent
and 123I2 intravenously for SPECT-scanning. After the SPECT/CT-scan,
mice received 131I2 or PBS intraperitoneally. The iodide uptakes were
calculated weekly and normalized to the injected dose of 123I2. (a)
Individual tumor uptake of 123I2 (the imaging isotope) in Ad5/3-hTERT-
hNIS and Ad5/3-hTERT-hNIS+131I2 -treated mice. All mice received 123I2
for evaluation of iodide uptake by SPECT. Mice in the latter group also
received 131I2 right after the SPECT imaging for therapeutic purposes.
Solid grey line, background level in the absence of Ad5/3-hTERT-hNIS;
dotted grey lines, 6 SD of background. (b) 123I2 uptake in the thyroids.
Results are expressed as %ID/mm361000 6 SD.
doi:10.1371/journal.pone.0032871.g004
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for the virus, including stromal and necrotic areas. Radiation,
however, could exert effects on, over and through such areas. Also,
some cells are or become resistant to radiation or oncolysis
[35,36]. In this context, the strong synergy between oncolytic
adenoviruses and radiation could be useful [4,37] as suggested in
previous reports [7,9,38,39]. However, since there was no
significant difference to the virus only in our experiment, construct
design issues may play a role in the relative impact of oncolysis
versus iodine mediated killing. In the context of optimized viral
replication, a large sample size or an immune competent organism
(where the efficacy of oncolysis could be less prominent) may be
needed for demonstrating if there is any benefit of the combination
in terms of efficacy.
Autopsies performed at the end of imaging experiment
suggested that tumor masses were larger than what were observed
by SPECT-imaging. Thus, the virus might not have been
simultaneously replicating in the entire tumor and only the part
of the tumor that sustains active replication at the time of imaging
would be positive for hNIS-expression – uninfected or dead tissue
would not be detected. The heterogeneity of the tumor mass might
also contribute: although hTERT-activation would be detected in
the parental tumor cells, the rapidly growing tumor bulk could
allow for variation in hTERT-promoter activity, and thus in hNIS
expression, due to mutations and inactivations of regulatory
factors like the E-box motifs, which have been suggested to be the
major determinants of hTERT-expression [40,41]. Furthermore,
intratumoral barriers including stromal, necrotic, hyperbaric and
hypoxic areas are likely to hamper the penetration of the virus to
the entire tumor resulting in an uneven distribution of hNIS-
expression. Incomplete tumor transduction due to polarized
expression of viral receptors could also play a role [42]. Finally,
as predicted by the mechanism of the virus, only tumor areas
through which the virus replication front is proceeding would be
expected to be positive for hNIS. Areas in which virus replication
has already occurred, would not be hNIS-positive, as cells that
allowed for replication would have been lysed. Alternatively,
oncolytic treatment might render tumor vasculature leaky or
create local hypobaric areas resulting in areas of hNIS-indepen-
dent iodine influx. This possibility could not be excluded since
treatment with control virus was not assessed in the systemic
approach. Also, in some tumors, only a small proportion of cells
are malignant [43,44], while the rest are murine-derived stromal
(not permissive for adenovirus replication) and the latter would
remain after oncolysis.
Visualization of the thyroid confirmed the utility of SPECT
imaging in the context of radioiodide therapy. Notably, all mice
treated with 131I showed diminished 123I2 uptake by the thyroid
during 2nd and 3rd week of the treatment. There are, however,
differences regarding hNIS-expression as a transgene or as a
regulator of the endocrine system. Importantly, extrathyroidal
tissues expressing hNIS are unable to organify iodide and their
hNIS-expression is not regulated by thyroid stimulating hormone
(TSH) [45]. In contrast, hNIS-expression in the thyroid is directly
Figure 5. Increasing amount of 123I2 accumulates in the tumor
over time showing progressive virus replication and increasing
tumor hNIS-expression. (a) SPECT/CT image (sagittal section)
showing 123I2 accumulation into tumor in the lungs of a mouse
treated intravenously with Ad5/3-hTERT-hNIS and intraperitoneally with
131I2. (b) Control mouse treated with 131I2 only shows no 123I2 -
accumulation in the lungs on the course of the treatment. (c)
Transverse section of the lungs of the mouse shown in (a) shows
accumulation of 123I2 into the tumor on the third treatment week. (d)
Transverse section of lungs of the mouse shown in (b) shows no
accumulation of 123I2 into the tumor on the third treatment week. The
crossing point of red lines indicates tumor localization.
doi:10.1371/journal.pone.0032871.g005
Table 1. Number of mice positive for uptake of the imaging
isotope 123I at the tumor.
Day
Group 1 7 14
Ad5/3-hTERT-hNIS alone 0 (2) 2 (2) 1 (2)
Ad5/3-hTERT-hNIS+131I 1 (3) 1 (3) 3 (3)
131I alone 0 (2) 0 (2) 0 (2)
Mock 0 (2) 0 (1) -
The total number of mice analyzed at each time point is given in parentheses.
Day indicates the day after first intravenous virus injection. -, not analyzed.
doi:10.1371/journal.pone.0032871.t001
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regulated by serum iodine concentration and TSH [46]. TSH
expression and secretion, in turn, are regulated by thyroxin and
triiodothyronine, and their relationship is inversely correlated [47].
Thus, the thyroid could be protected from 131I either by iodine- or
thyroxin-supplementation prior to therapy. The latter has been
successfully used in glioma treatment with a lentiviral vector
expressing hNIS [48]. The study reported a lack of thyroidal NIS-
expression and function after a thyroxin supplemented diet
whereas hNIS-transduced tumor tissue could be simultaneously
visualized.
Excess iodine decreases NIS mRNA and protein expression
[49], reduces radioiodide accumulation into the thyroid and can
protect the thyroid for 24 h when administered up to two hours
prior to 131I [50]. If the same timing of Ad5/3-hTERT-hNIS and
131I would apply in a clinical setting, extra-iodine administered 4–
6 hours after virus injection would saturate the thyroid without
hampering transgene-mediated transportation of radioiodide into
the tumor after 131I administration (eg. at 24 hours as in our
experiments). However, lack of organification of radioiodide into
cancer tissues is also a drawback as it reduces accumulation and
subsequent dose to the tumor. A rapid radioiodide efflux from
tumor cells has been associated with exogenous hNIS-expression
[51] and it is clear that this issue is critical in our approach.
Another problem may arise from viral oncolysis resulting in the
death of the hNIS-expressing cells that limits the duration of the
hNIS-expression window. The ‘‘timed’’ expression system used in
Ad5/3-hTERT-hNIS, where transgene-expression starts at circa
8 h after infection (and thus closer to oncolysis), may limit the
window further. In this regard, a ubiquitous CMV-promoter with
high early activity might result in higher hNIS-expression levels
[52,53]. When adenoviral vectors are delivered systemically, they
are rapidly taken up by liver Kuppfer cells (KC) [30]. The
phenomenon is dose dependent and saturation occurs after high
intravenous doses [54] leading to efficient transduction of
hepatocytes and other tissues. Adenoviral entry into hepatocytes
together with KC activation can result in an immune response that
is suggested to be the major determinant of adenovirus induced
toxicity [55]. However, if the injected doses are small enough to
avoid acute hepatotoxicity, but sufficient to saturate KC, transgene
expression in hepatocytes occurs. This provokes a second,
adenovirus-protein -specific immunoresponse [56]. Thus, the use
of tumor-specific promoters to restrict expression of adenoviral
proteins to tumors is important from a safety perspective. Indeed,
previous work has shown that hTERT-regulated expression of
E1A in an oncolytic adenovirus did not induce liver toxicity [57].
Accordingly, minimal hepatic hNIS-expression was seen in our
study.
Human adenovirus is fairly human-specific and thus mice are
poor models for studying toxicity. Ultimately, human trials may be
needed to evaluate the feasibility and safety of intravenous
injection at doses compatible with efficacy. Oncolytic adenoviruses
might currently be the best administered intratumorally or
intracavitary, perhaps in combination with intravascular delivery.
Nevertheless, there are some tantalizing cases suggesting efficacy
even after intravenous delivery alone [3,58]. However, immuno-
genicity of adenoviruses is an issue with regard to systemic re-
administration [59].
In conclusion, Ad5/3-hTERT-hNIS was found to have anti-
tumor activity in vitro, and in vivo it extended the survival of mice.
Intriguingly, SPECT/CT imaging suggested that hNIS-expression
could be detected only in a proportion of the tumor mass, which is
likely due to incomplete penetration after systemic administration.
Accordingly, combination therapy was not more effective than
virus alone. However, an increasing level of hNIS-expression
during therapy was detected using SPECT/CT, demonstrating
the utility of the method for dynamic imaging of radioiodide
therapy in animals with complex orthotopic human cancer
xenografts. Before considering the possible clinical translation of
the combination therapy to humans, further work is needed for
improving tumoral hNIS expression levels and consequently 131I-
targeting efficiency [52].
Materials and Methods
Cell lines
Castration resistant prostate cancer cell lines 22Rv1, PC-3 and
DU-145 and human embryonic kidney epithelial cell line 293 were
purchased from American Type Culture Collection (ATCC,
Manassas, VA). PC-3MM2 cells are a metastatic, castration
resistant subline of PC-3 (courtesy of Isaiah J. Fidler, M. D.
Anderson Cancer Center). 911 cells were obtained from Dr. Alex
J. van der Eb (University of Leiden, The Netherlands). All cell lines
were cultured as previously described [7]. PC-3 and DU-145 cells
have been confirmed to have hTERT-expression [60].
Viral constructs
Wild type adenovirus serotype 5 (Ad5 WT) was purchased from
ATCC. Ad5/3luc1 has been described earlier [22].
Cloning
hTERT-fragment was amplified by PCR from pBT255
(Courtesy of Izumi Horikawa, National Cancer Institute) to create
a shuttle vector for E1-region. The following primers were used to
result in 361 bp sized amplification product: forward primer, 59-
TTA GCG GCC GCA GAA CAT TTC TCT ATC GA-39 and
reverse primer, 59-ACC GGA ATG CCA AGC TTA CTT AGA
T -39. NotI-XhoI- digested hTERT-fragment was inserted into
NotI-XhoI -digested and calf intestinal alkaline phosphatase
(CIAP) -treated pSE1AmpR (constructed previously in the
laboratory) to obtain phTERTE1AmpR. Next, both PmeI -
linearized phTERTE1AmpR and circular pAdEasy-1.5/3-D24
[61] were electroporated into BJ5183 cells for homologous
recombination resulting in pAdEasy-hTERT-E1-5/3. DNA from
selected recombinant clones was electroporated into DH5a cells
for DNA production and further analysis.
To obtain phTERT-E1-5/3-hNIS and phTERT-E1-5/3-
Dgp19K, SrfI-linearized pAdEasy-hTERT-E1-5/3 and FspI –
linearized pTHSN-hNIS or FspI –linearized pTHSN-Dgp19K [7]
were electroporated into BJ5183 cells for homologous recombi-
nation. The DNA from selected recombinant clones was
electroporated into DH5a cells for DNA-production and further
analysis. phTERT-E1-5/3-hNIS and phTERT-E1-5/3-Dgp19K
were linearized and transfected into 911 cells using Superfect
(Qiagen, Hilden, Germany). The viruses were plaque-purified and
propagation was performed on A549 cells followed by standard
CsCl purification to obtain a concentration of 4.861011 viral
particles/ml (vp/ml) and 1.861010 plaque forming units/ml (pfu/
ml) for Ad5/3-hTERT-hNIS and 561011 vp/ml and 5.161010 pfu/
ml for Ad5/3-hTERT-Dgp19K.
Reverse transcription –PCR (RT-PCR)
Prostate cancer cells were infected with 10 vp/cell of Ad5/3-
hTERT-hNIS or Ad5/3-hTERT-Dgp19K for 2 h in 37uC. 24 h
and 48 h after infection total RNA was isolated (RNeasy Kit,
Qiagen). The samples were treated with DNase before subjected to
RT-PCR. 350 ng of RNA was used for each reaction. Amplifi-
cation was done using OneStep Reverse Transcription –PCR Kit
(Qiagen) with 35 cycles and annealing at 54uC. The hNIS-PCR
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product size (453 bp) was obtained using hNIS-specific primers
(forward 59-CTTCTGAACTCGGTCCTCAC-39 and reverse
59-TCCAGAATGTATAGCGGCTC-39). For ß-actin, (482 bp
product size) was obtained using for human ß-actin-specific
primers (forward 59-CGAGGCCCAGAGCAAGACA-39 and
reverse 59-CACAGCTTCTCCTTAATGTCACG-39).
Iodine uptake in vitro
16105 PC-3, PC-3MM2, DU-145 and 22Rv1 cells/well were
plated, incubated overnight, and next day infected with 10 vp/cell
of Ad5/3-hTERT-hNIS or Ad5/3-hTERT-Dgp19K for two
hours. 24 h or 48 h later the cells were washed with PBS and
[125I]NaI (MAP Medical Technologies Oy, Finland) was added for
20 min at RT. Cells were washed twice with PBS and 300 ml/well
of Cell Culture Lysis Reagent (Promega, Fitchburg, WI) was
added. Radioactivity was quantified as described in [7].
Cell killing assays
10,000 cells/well were seeded on 96-well plates, incubated
overnight and next day infected with Ad5/3-hTERT-hNIS, Ad5/
3-hTERT-Dgp19K, Ad5/3luc1 or Ad5 wild type (0.01–100 vp/
cell) for 2 h. The viability of the cells was assessed on day 6 (PC-
3MM2), day 7 (PC-3 and DU-145) or day 9 (22Rv1) using the
MTS-assay (CellTiter 96 Aqueous One Solution cell proliferation
assay, Promega). The cell survival after infection was followed
daily with internal controls and the stopped when an almost
complete cell killing was seen with the fastest virus [24].
Iodine uptake in vivo
The protocol was identical as described in [7]. NMRI/nude
mice (Taconic, Ejby, Denmark) were injected with 76108 vp of
Ad5/3-hTERT-hNIS, Ad5/3-hTERT-Dgp19K or saline.
In vivo survival and biodistribution
NMRI/nude mice (n = 15/group) were purchased from Taco-
nic. 1.56106 PC-3MM2 cells were inoculated into the left lung of
the mice under medetomidine-ketamine anesthesia (day 0) [4,7].
On day 7, mice were randomized into four groups; mock, 131I
alone, Ad5/3-hTERT-hNIS alone or 131I+Ad5/3-hTERT-hNIS
and received 561010 vp of Ad5/3-hTERT-hNIS or DMEM
intravenously. The next day, animals were injected with
3665 MBq of [131I]NaI (MAP Medical Technologies) in 16PBS
or vehicle intraperitoneally. Three animals from each group were
sacrificed 24 hours after the first 131I-treatment for the biodis-
tribution study where radioactivity was measured with an
automated gamma-counter (Perkin Elmer Wizard 3, Perkin
Elmer, Waltham, MA). Results are expressed as percentage from
the initial iodine-dose/g of tissue. 12 mice/group continued in the
survival experiment and the same doses were repeated once a
week for 3 weeks.
hNIS-expression in vivo by SPECT/CT
NMRI/nude male mice (Harlan, Indianapolis, IN) were treated
identical to the survival-experiment. The animals were scanned
with SPECT/CT a day after each intravenous Ad5/3-hTERT-
hNIS or DMEM injection, three times in total. The 131I
(3266 MBq) or PBS-injections were given after the SPECT/
CT-scan.
1862 MBq of sterile [123I]NaI (MAP Medical Technologies)
was injected intravenously under isoflurane-anaesthesia for
SPECT-imaging (that was performed 2 h after 123I injections).
SPECT/CT was acquired using multi-pinhole nanoSPECT/CT-
system with four heads (Bioscan, Washington DC). SPECT-
acquisition collected 30 000 counts per projection (16-projections)
and the scan-time was 20–25 min. After the third scan mice were
sacrificed and the tumors were harvested. All images were
reconstructed with MEDISO-software and analyzed using In
Vivo Scope-software (both Medical Imaging Systems, Kingsbury,
England). Voxel-guided regions of interest (ROI) were drawn
using the fused SPECT/CT-images and the results are expressed
as percentage of radioactivity in the ROI from the injected activity
(at time of the SPECT-scan), divided by the volume of the ROI
(in mm3).
Statistical analysis
Student’s t-tests were performed to analyze in vitro iodide uptake
and cell killing using Microsoft Excel (Microsoft Corporation,
WA). Survival analyses were conducted by plotting Kaplan-Meier
curves, and the comparisons between groups were done pairwise
by the log-rank procedure with PASW statistics 17.0 (SPSS Inc.,
Chicago, IL). For all analyses, a two-tailed p-value,0.05 was
deemed statistically significant.
Ethics statement
The animal experiments were approved by the National
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Supporting Information
Figure S1 hNIS-expression from Ad5/3-hTERT-hNIS is
restricted to tumor cells. A mouse treated with Ad5/3-
hTERT-hNIS shows minimal liver 123I2 accumulation after the
first intravenous injection of the virus (week 1). The next
treatments (weeks 2 and 3) did not result in hepatic uptake.
(TIF)
Video S1 The video shows tumor-specific hNIS-expres-
sion on the third treatment week in the lung of a mouse
treated with Ad5/3-hTERT-hNIS and 131I2. Some physio-
logical uptake is seen in esophagus, thyroid and salivary glands.
(GIF)
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